Global Arbovirus Testing Market Expected to Reach USD 4.67 Billion...

Global Arbovirus Testing Market Expected to Reach USD 4.67 Billion by 2031 Due to Outbreak Preparedness and Diagnostic Innovation

Veröffentlicht 2025-06-05 09:17:39

725

[Geneva, 5th June 2025] – Clearview Market Insights (CVMI) forecasts that the global arbovirus testing market will grow from USD 1.84 billion in 2024 to USD 4.67 billion by 2031, achieving a robust compound annual growth rate (CAGR) of 14.2 percent. This expansion is driven by an increase in vector-borne disease outbreaks, heightened investment in public health surveillance, and rapid advancements in field-deployable diagnostics.

“Arbovirus testing is no longer seasonal or regional—it’s a core component of global outbreak intelligence and pandemic prevention,” said Dr. Martin Alvarez, infectious disease diagnostics lead at CVMI. “The convergence of AI, mobile diagnostics, and next-gen serology is transforming how health systems detect, report, and respond to vector-borne threats.”

Request Sample @ https://clearviewmarketinsights.com/report-details/global-arbovirus-testing-market/

Key Numbers

2024 Market Value: USD 1.84 billion
2031 Market Value: USD 4.67 billion
Seven-Year CAGR: 14.2 percent
Dengue Testing Share (2024): 41%
Asia-Pacific Market Share: 39%

Market Drivers

Climate-driven spread of mosquitoes and ticks
Global health funding for early detection
Urban travel and international disease transmission
WHO, CDC, and PAHO-led surveillance initiatives
Demand for rapid, field-ready diagnostics

Company Highlights

Abbott rolled out dual-target RDTs across high-burden countries.
Roche added Liat-compatible arbovirus test panels for fast deployment.
Thermo Fisher established mobile labs in the Caribbean with portable qPCR.
Bio-Rad launched ELISA tools that distinguish between co-circulating flaviviruses.

Regional Insights

Asia-Pacific: Dengue and chikungunya dominate public testing programs.
Latin America: Brazil, Colombia, and Peru invest in decentralized arbovirus labs.
Africa: Surveillance rising for Rift Valley Fever and West Nile virus.
North America/Europe: Focus on travel medicine and integrated vector surveillance.

2024–2025 Milestones

Quarter	Event	Impact
Q1 2024	WHO prequalifies 2 new multiplex kits	Accelerates field deployment in Southeast Asia
Q2 2024	Thermo Fisher launches mobile PCR labs	Caribbean islands improve real-time detection capacity
Q3 2024	Bio-Rad introduces differential IgM panels	Boosts diagnostic accuracy during co-outbreaks
Q1 2025	Qiagen expands vector surveillance portfolio	Strengthens qPCR diagnostics in Africa and LATAM

For more insights, visit https://clearviewmarketinsights.com/

About Clearview Market Insights

Clearview Market Insights is a leading provider of global infectious disease diagnostics research, offering forward-looking insights across more than 100 disease surveillance and laboratory technology markets. We assist stakeholders in aligning innovation with public health priorities through data, forecasting, and strategic guidance.

Media contact:

Bhavani K

Marketing and Sales Head

ClearView Market Insights

Mail: sales@clearviewmarketinsights.com

Phone: +1 917-993-7369